



Summary of MS treatments

More detail on each of these medications can be found in our **medications factsheets** that summarise the key information, including potential side effects, to provide you with background information that you can then discuss with your healthcare providers.

	Disease Modifying Therapies (DMTs)											Symptomatic Therapies			
	oral tablet				injection					infusion					
Brand name	Aubagio® note 1	Gilenya®	MAVENCLAD®	Tecfidera®	Avonex®	Betaferon®	Copaxone®	Plegridy®	Rebif®	Lemtrada®	Ocrevus®	Tysabri®	Botox®	Fampyra®	Sativex®
Generic name	teriflunomide	fingolimod	cladribine tablets	dimethyl fumarate	interferon b-1a	interferon b-1b	glatiramer acetate	interferon b-1a (pegylated)	interferon b-1a	alemtuzumab	ocrelizumab	natalizumab	botulinum toxin type A	fampridine	nabiximols
Manufacturer	Sanofi Genzyme	Novartis Australia	Merck	Biogen	Biogen	Bayer Australia	Teva	Biogen	Merck Serono	Sanofi Genzyme	Roche	Biogen	Allergan	Biogen	Emerge Health Pty Ltd
Indications (forms of MS that the treatment is used for)	Relapsing remitting MS (RRMS)	Relapsing forms of MS (RRMS and relapsing SPMS)	RRMS	RRMS	RRMS	Single clinical event indicating high risk of MS, RRMS, SPMS	Single clinical event indicating high risk of MS & RRMS	RRMS	Single clinical event indicating high risk of MS & RRMS	RRMS	RRMS & Primary Progressive MS (PPMS)	RRMS (Use in paediatric patients with RRMS subject to Gov't approval)	Any form of MS; for treatment of urinary incontinence	Any form of MS; to improve walking	Muscle stiffness (spasticity)
Route	oral tablet	oral capsule	oral tablet	oral capsule	intramuscular injection	subcutaneous injection	subcutaneous injection	subcutaneous injection	subcutaneous injection	intravenous infusion	intravenous infusion	intravenous infusion	intramuscular injection	oral tablet	oromucosal (mouth) spray
Dosage and Frequency	one 14 mg tablet per day	Adults and paediatric patients over 40 kg: one 0.5 mg capsule per day Paediatric patients 40kg and under: 0.25mg capsule per day	Two treatment courses over two years; each treatment course consists of two weeks.	one 120mg capsule twice daily, increasing to 240g twice daily	once per week	every two days	40 mg, three times per week OR 20 mg daily (20 mg dose not available after 1-7-19)	every two weeks	three times per week	two treatment courses, 1 year apart	6 monthly; first treatment is split into 2 doses a fortnight apart	every 28 days	single treatment	Two tablets per day, 12 hours apart	A number of sprays per day depending on individual circumstances
Preparation	film coated oral tablet	gel capsules	uncoated tablets	capsule	pre-filled syringe	pre-filled syringe	pre-filled syringe	single-use, pre-filled injection pens	pre-filled cartridge	prepared by pharmacy or clinic staff	prepared by pharmacy or clinic staff	prepared by pharmacy or clinic staff	multiple injections by doctor during one visit	film coated oral tablet	10mL glass spray container and a pump
Storage	room temperature, below 30°C	room temperature, below 30°C	room temperature, below 25°C	room temperature, below 30°C	refrigerate 2-8°C	room temperature, below 25°C	refrigerate 2-8°C	refrigerate 2-8°C	refrigerate 2-8°C	stored in the pharmacy or clinic at 2-8°C	stored in the pharmacy or clinic at 2-8°C	stored in the pharmacy or clinic at 2-8°C	doctor will arrange storage	room temperature, below 25°C	refrigerate 2-8°C
Available on PBS	Yes	0.5mg dosage capsules - yes 0.25mg capsules - subject to Gov't approval	Yes (from 1 Jan 2019)	Yes	Yes	Yes, RRMS only, not for single clinical event	Yes, RRMS only, not for single clinical event. 20 mg dose deleted from PBS from 1-7-19	Yes	Yes, RRMS only, not for single clinical event	Yes	RRMS Yes PPMS No	Yes	Yes	No	No

Note 1: A generic version of teriflunomide is now available, please visit: <https://www.msaustralia.org.au/about-ms/medications-treatments>